Report scope. This 2026 Drug Asset Due Diligence Report evaluates Iscalimab as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: HOLD / OPTION
Iscalimab is a Monoclonal antibody associated with CD40 and a global highest development stage of Phase 2. The lead disclosed indication is Hidradenitis Suppurativa. The current evidence supports a HOLD / OPTION posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Iscalimab
- Target: CD40
- Lead indication: Hidradenitis Suppurativa
- Highest phase: Phase 2
- Matched trials: 0
- Matched result records: 12
- Matched asset deals: 0
Use PatSnap Life Sciences MCP servers to validate the Iscalimab diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Iscalimab, the MCP profile identifies CD40 as the primary target context and Hidradenitis Suppurativa as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Iscalimab diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| No asset-specific registered study was returned by the MCP query. Confirm sponsor records and registry synonyms before a licensing decision. | ||||
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Iscalimab diligence evidence.
3. Clinical readouts: what is known
A TWINSS Extension Trial to Evaluate the Safety and Tolerability of CFZ533 (Iscalimab) at Two Dose Levels Administered Subcutaneously in Patients With Sjögren's Syndrome
Study: NCT04541589 (TWINSS Extn, CTgov). Phase: Phase 2. Enrollment: 206. Published: 2025-06-29.
death = 0 Pts | death = 0 Pts
1214-P: Iscalimab in Adolescents and Young Adults with New-Onset Type 1 Diabetes
Study: NCT04164206 (ADA2025). Phase: Phase 2. Enrollment: 44. Published: 2025-06-20.
C-peptide(1 year): P-Value = 0.18 | C-peptide(1 year): P-Value = 0.18
Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM)
Study: NCT04129528 (CCFZ533X2207, CTgov). Phase: Phase 2. Enrollment: 44. Published: 2025-01-17.
AE = 28 Pts | AE = 13 Pts
A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Two Regimens of Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additionalr Follow-up and a Long-term Extension (CONTRAIL I)
Study: NCT03781414 (CONTRAIL I, CTgov). Phase: Phase 2. Enrollment: 129. Published: 2024-07-03.
Percentage of Patients With Composite Event (Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death) Over 12 Months = 8 Pts | Percentage of Patients With Composite Event (Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death) Over 12 Months = 12 Pts
SAFETY AND EFFICACY OF ISCALIMAB IN PATIENTS WITH SJÖGREN’S DISEASE: 48-WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
Study: NCT03905525 (TWINSS, EULAR 12024 | EULAR 22024). Phase: Phase 2. Enrollment: Not disclosed. Published: 2024-06-12.
ESSDAI = -7.6 Unit | ESSDAI = -5.7 Unit
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial
Study: NCT02713256 (Pubmed | J Clin Endocrinol Metab). Phase: Phase 2. Enrollment: 15. Published: 2020-03-01.
Clinical Response = 47 %
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Study: NCT02291029 (CTgov). Phase: Phase 2. Enrollment: 69. Published: 2019-08-14.
Baseline(Mean) = 12.0 Unit | Baseline(Mean) = 11.8 Unit
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis
Study: NCT02565576 (CTgov). Phase: Phase 2. Enrollment: 44. Published: 2019-07-25.
Mean Change From Baseline in the Quantitative Myastenia Gravis (QMG) Score at Week 25. Posterior Median Was Used as Measure Type.(Median) = -4.07 Point (90%CI, -5.67 to -2.47) | Mean Change From Baseline in the Quantitative Myastenia Gravis (QMG) Score at Week 25. Posterior Median Was Used as Measure Type.(Median) = -2.93 Point (90%CI, -4.53 to -1.33)
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
Study: NCT02217410 (Corporate Publications). Phase: Phase 1/2. Enrollment: Not disclosed. Published: 2019-06-06.
CADI = lower CADI scores compared with tacrolimus | CADI = lower CADI scores compared with tacrolimus
OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism
Study: OR19-6 (ENDO2019). Phase: Phase 1. Enrollment: 15. Published: 2019-04-30.
Adverse Event: Adverse events = Most events were mild in nature (34 in 8 patients, 53.3%) and few were moderate (5 in 4 patients, 26.7%)
A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients
Study: NCT02217410 (CCFZ533X2201, CTgov). Phase: Phase 1/2. Enrollment: 59. Published: 2018-12-21.
Mean Cmax Pharmacokinetic Parameter- Part I(Mean) = 66.3 µg/mL | Month 3 = 6 Event
An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease
Study: NCT02713256 (CTgov). Phase: Phase 2. Enrollment: 15. Published: 2018-05-21.
Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment = 0 %
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Iscalimab diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Iscalimab against approved therapies and clinical competitors in Hidradenitis Suppurativa, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Iscalimab diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| No exact asset-specific transaction was returned. Use target-level precedents only as comparables and do not present them as asset transactions. | ||||
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Iscalimab diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
HOLD / OPTION
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
